IQI0 Stock Overview A clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Incannex Healthcare Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Incannex Healthcare Historical stock prices Current Share Price US$1.43 52 Week High US$1.78 52 Week Low US$1.43 Beta 2.09 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO -86.32%
Recent News & Updates
Incannex Healthcare Receives Non-Compliance Notice from Nasdaq Regarding Market Value of Listed Securities Jan 11
Incannex Healthcare Inc., Annual General Meeting, Dec 11, 2024 Nov 02
Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer Oct 25
Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial Aug 06
Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X Jul 30 Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jul 04
See more updates
Incannex Healthcare Receives Non-Compliance Notice from Nasdaq Regarding Market Value of Listed Securities Jan 11
Incannex Healthcare Inc., Annual General Meeting, Dec 11, 2024 Nov 02
Incannex Healthcare Inc. Announces Appointment of Dr. Lou Barbato as Chief Medical Officer Oct 25
Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial Aug 06
Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X Jul 30 Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jul 04
Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea May 31
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder May 09
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N Feb 17
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis Jan 25
Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder Jan 19
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea Jan 17
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia Dec 22
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea Dec 06 Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity
Incannex Healthcare Limited Files Form 15 Nov 30
Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration Aug 25
Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States Aug 23
Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis Jul 27
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea Jul 23
Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675 Jul 14
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea Jul 07
Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial Jun 17
Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin Jan 19 Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X Dec 08
Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea Nov 17
Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial Oct 13
Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury Oct 11
Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022 Oct 07
Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors Aug 17
Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders. Aug 06
Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A Aug 03
Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A Jul 21
Incannex Healthcare Limited Announces Board Changes Jun 29
Incannex Healthcare Limited Approves Election of George Anastassov as Director Jun 09
Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea Jun 03
Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea May 18
Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022. May 12 Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion May 10
Shareholder Returns IQI0 DE Pharmaceuticals DE Market 7D 0% 2.5% 1.3% 1Y n/a -15.2% 9.0%
See full shareholder returns
Return vs Market: Insufficient data to determine how IQI0 performed against the German Market .
Price Volatility Is IQI0's price volatile compared to industry and market? IQI0 volatility IQI0 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IQI0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IQI0's volatility change over the past year.
About the Company Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.
Show more Incannex Healthcare Inc. Fundamentals Summary How do Incannex Healthcare's earnings and revenue compare to its market cap? IQI0 fundamental statistics Market cap €59.85m Earnings (TTM ) -€12.23m Revenue (TTM ) €620.84k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IQI0 income statement (TTM ) Revenue AU$1.01m Cost of Revenue AU$0 Gross Profit AU$1.01m Other Expenses AU$20.99m Earnings -AU$19.98m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -0.013 Gross Margin 100.00% Net Profit Margin -1,970.61% Debt/Equity Ratio 0%
How did IQI0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/12/04 08:30 End of Day Share Price 2023/09/06 00:00 Earnings 2023/06/30 Annual Earnings 2023/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Incannex Healthcare Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Arron Aatkar Edison Investment Research David Joseph Storms Stonegate Capital Partners, Inc.
Show 0 more analysts 